Weight Loss Programs

---

Semaglutide is weekly injectable that binds to the GLP-1 receptors which are located on the beta receptors of the pancreas and areas of the brain. Binding increases insulin secretion which lowers glucose levels, reduces post-prandial glucagon secretion, promotes early satiety, slows down gastric emptying, and helps regulate appetite & cravings.

Yes, Semaglutide was approved for weight loss by the FDA in 2021. 

Semaglutide Function on Specific Organs:

• Brain:  Helps Regulate appetite and cravings
• Stomach: Slows down emptying of stomach after meals
• Pancreas:  Increase insulin production to help regulate glucose levels
• Liver: Reduces production of glucose

Aside from weight loss, patients taking Semaglutide have also seen a decreased risk of certain conditions like cardiovascular disease, diabetes, joint pain and reduced blood pressure.

The side effects of semaglutide are typically mild — especially when compared to the complications associated with overweight and obesity.

People taking semaglutide for weight loss may experience:

• Dizziness
• Fatigue
• Gastrointestinal issues, such as diarrhea, constipation and gassiness
• Headache
• Stomach issues, including nausea, vomiting, pain or distension (bloat)

Gastrointestinal issues are the most common complaint among people just starting semaglutide. But you may be able to reduce the side effects by beginning on a lower dose and then slowly increasing the amount you take.

While patients will notice some significant body weight loss in the first month, the full benefits are usually fully noticed after three to six months of treatment. (Results may vary based on treatment plan)

Semaglutide is a medication that is increased over time.  This allows your body to adjust and tolerate the medication better. If you start a high dose, you will have an increased risk of side effects such as nausea, diarrhea, constipation, and abdominal pain.

Tirzepatide activates receptors of hormones secreted from the intestine (glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) to reduce appetite and food intake. Tirzepatide is administered by injection under the skin once weekly, and the dosage must be increased over four to 20 weeks to achieve the target dosages of 5 milligram (mg), 10 mg or 15 mg once weekly. The maximum dosage of Tirzepatide is 15 mg once weekly.

Yes, Tirzepatide was approved for weight loss by the FDA in 2023. 

Tirzepatide Function on Specific Organs:

• Brain:  Helps Regulate appetite and cravings
• Stomach: Slows down emptying of stomach after meals
• Pancreas:  Increase insulin production to help regulate glucose levels
• Liver: Reduces production of glucose

Aside from weight loss, patients taking Tirzepatide have also seen a decreased risk of certain conditions like cardiovascular disease, diabetes, joint pain and reduced blood pressure.

The side effects of Tirzepatide are typically mild — especially when compared to the complications associated with obesity and being overweight.

People taking Tirzepatide for weight loss may experience:

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Abdominal Discomfort & Pain
• Injection Site Reactions
• Fatigue
• Hypersensitivity (allergic) Reactions (typically fever & rash)
• Indigestion
• Gastroesophageal Reflux
• Hair Loss

Gastrointestinal issues are the most common complaint among people just starting Tirzepatide. You may be able to reduce the side effects by beginning on a lower dose and then slowly increasing the amount you take.

While patients may notice some body weight loss in the first month, the full benefits are usually fully noticed after three to six months of treatment. (Results may vary based on treatment plan)

Tirzepatide is a medication that is increased over time.  This allows your body to adjust and tolerate the medication better. If you start a high dose, you will have an increased risk of side effects such as nausea, diarrhea, constipation, and abdominal pain.

Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether Tirzepatide causes such tumors, including medullary thyroid cancer, in humans. Tirzepatide should not be used in patients with a personal or family history of medullary thyroid cancer or in patients with Multiple Endocrine Neoplasia syndrome type 2.